

Edgar Filing: MEDCOM USA INC - Form 10QSB

MEDCOM USA INC
Form 10QSB
September 18, 2002

=====

U.S. Securities and Exchange Commission
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

For the quarterly period ended December 31, 2001

Transition Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act

For the transition period from N/A to N/A

Commission File No. 0-25474

MEDCOM USA, INCORPORATED
(Name of small business issuer as specified in its charter)

DELAWARE
State of Incorporation

65-0287558
IRS Employer Identification No.

7975 NORTH HAYDEN ROAD, SUITE C-260
SCOTTSDALE, AZ 85258
(Address of principal executive offices)

(480) 675-8865
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

Yes _____ No _____ X _____

The number of shares of the issuer's common equity outstanding as of
January 31, 2002 was 29,518,080 shares of common stock.

Transitional Small Business Disclosure Format (check one):

Yes _____ No _____ X _____

Edgar Filing: MEDCOM USA INC - Form 10QSB

INDEX TO FORM 10-QSB FILING
FOR THE THREE MONTHS ENDED DECEMBER 31, 2001

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION	PAGE
Item 1. Financial Statements	
Balance Sheet	
As of December 31, 2001	3
Statements of Operations	
For the Three and Six Months Ended December 31, 2001 and 2000	4
Statements of Cash Flows	
For the Six Months Ended December 31, 2001 and 2000	5
Notes to the Financial Statements	6 - 8
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	9 - 12

PART II OTHER INFORMATION

Item 1. Legal Proceedings	13
-------------------------------------	----

SIGNATURES

CERTIFICATION

PART 1. FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS

MEDCOM USA, INC.
CONSOLIDATED BALANCE SHEET (UNAUDITED)
DECEMBER 31, 2001

ASSETS

CURRENT ASSETS:

Cash	\$	5,343
Accounts receivable, net of allowance of \$300,765		52,387
Notes receivable		82,000
Inventories		72,711
Prepaid expenses and other current assets		10,250

Total current assets		222,691
----------------------	--	---------

PROPERTY AND EQUIPMENT, net		565,497
GOODWILL, net of accumulated amortization of \$246,675		512,323
OTHER ASSETS		44,976

Edgar Filing: MEDCOM USA INC - Form 10QSB

TOTAL ASSETS	\$ 1,345,487
	=====
LIABILITIES AND STOCKHOLDERS' EQUITY	
CURRENT LIABILITIES:	
Accounts payable	\$ 1,148,299
Accrued expenses and other liabilities	1,330,712
Dividend payable	23,750
Notes payable	106,589
Capital lease - current portion	15,039

Total current liabilities	2,624,389
Deferred Gain	44,574
Capital lease - long-term portion	62,995

Total liabilities	2,731,958

STOCKHOLDERS' EQUITY:	
Convertible preferred stock, Series A \$.001par value, 52,900 shares designated, 4,250 issued and outstanding.	4
Convertible preferred stock, Series D \$.01par value, 50,000 shares designated, 2,850 issued and outstanding.	29
Common stock, \$.0001 par value, 80,000,000 shares authorized, 29,193,231 issued and outstanding.	2,920
Paid in capital	62,365,082
Accumulated deficit	(63,754,506)

Total stockholders' equity	(1,386,471)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 1,345,487
	=====

See the accompanying notes to these unaudited financial statements.

3

MEDCOM USA, INC.
CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)
FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2001

	Three Months Ended		Six Months Ended	
	2001	2000	2001	2000
	-----	-----	-----	-----
REVENUES:				
Terminal sales	\$ 935	\$ 140,916	\$ 68,087	\$ 190,000
Rental	-	-	-	-
Service	133,677	102,061	181,568	170,000
Miscellaneous revenue	1,279	9,564	8,108	-
	-----	-----	-----	-----
Total	135,891	252,541	257,763	360,000
OPERATING EXPENSES:				
Cost of terminals and services	-	150,291	13,073	190,000
General and administrative expenses	511,357	1,449,195	1,653,681	2,740,000

Edgar Filing: MEDCOM USA INC - Form 10QSB

Sales and marketing expenses	-	435,689	1,342	62
Research and development	-	11,700	-	10
Professional and consulting fees	-	-	27,760	
Depreciation and amortization	88,492	187,175	212,973	38
Total operating expenses	599,849	2,234,050	1,908,829	4,04
OPERATING LOSS	(463,958)	(1,981,509)	(1,651,066)	(3,68
OTHER (INCOME) AND EXPENSES				
Interest expense	500	13,980	7,876	2
Interest income	-	(6,819)	-	(1
Total other expense	500	7,161	7,876	
INCOME TAX (BENEFIT) PROVISION	-	-	-	(
LOSS FROM CONTINUING OPERATIONS	(464,458)	(1,988,670)	(1,658,942)	(3,69
LOSS ON DISPOSAL OF ASSETS	-	-	(105,646)	
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	42,829	(626,401)	(10,476)	(71
NET LOSS	(421,629)	(2,615,071)	(1,775,064)	(4,40
Preferred stock dividend	(28,500)	(28,500)	(57,000)	(5
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS	(450,129)	(2,643,571)	(1,832,064)	(4,46
Foreign currency translation	-	(47,181)	-	(6
TOTAL NET COMPREHENSIVE LOSS	\$ (450,129)	\$ (2,690,752)	\$ (1,832,064)	\$ (4,52
NET LOSS PER SHARE:				
Basic:				
Continuing operations	\$ (0.02)	\$ (0.30)	\$ (0.08)	\$
Discontinued operations	-	(0.09)	-	
Total Basic	\$ (0.02)	\$ (0.39)	(0.08)	\$
Diluted:				
Continuing operations	\$ (0.02)	\$ (0.30)	\$ (0.08)	\$
Discontinued operations	-	(0.09)	-	
Total Diluted	\$ (0.02)	\$ (0.39)	\$ (0.08)	\$
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:				
Basic	26,175,713	6,813,209	21,524,998	6,62
Diluted	26,175,713	6,813,209	21,524,998	6,62

See the accompanying notes to these unaudited financial statements.

Edgar Filing: MEDCOM USA INC - Form 10QSB

4

MEDCOM USA, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE SIX MONTHS ENDED DECEMBER 31, 2001 AND 2000

	2001	2000
	-----	-----
CASH FLOWS FROM OPERATING ACTIVITIES		
NET LOSS	\$ (1,775,064)	\$ (4,408,
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Loss on disposal of assets	105,646	
Discontinued operations	10,476	716,
Depreciation and amortization	212,973	1,228,
Value of common stock and warrants granted as compensation for services	-	94,
Other	-	(55,
Payment of expenses through issuance of common stock	519,550	
Changes in assets and liabilities:		
Trade accounts receivable	46,841	117,
Inventories	45,888	(64,
Royalty advances	-	62,
Prepaid and other current assets	71,303	65,
Other assets	(1,415)	(50,
Accounts payable and accrued liabilities	222,037	178,
	-----	-----
Net cash used in continuing operations	(541,765)	(2,115,
Net cash used in discontinued operations	72,931	(636,
	-----	-----
NET CASH (USED IN) OPERATING ACTIVITIES	(468,834)	(2,752,
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of equipment	(78,034)	(1,111,
Proceeds on sale of equipment	-	
Advances on note receivable	(82,000)	(66,
Repayments under notes receivable	-	2,
	-----	-----
NET CASH (USED IN) INVESTING ACTIVITIES	(160,034)	(1,176,
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES		
Principal repayments on capital leases	(2,849)	(27,
Proceeds on sale of terminals under captial leases	78,034	
Principal repayments on notes payable	-	(2,
Proceeds from issuance of long-term debt	-	95,
Proceeds from the exercise of options and warrants	-	1,632,
Proceeds from sale of common stock	619,600	900,
Payment on bank draft	(60,574)	
Currency translation loss	-	(63,
	-----	-----
NET CASH PROVIDED BY FINANCING ACTIVITIES	634,211	2,533,
	-----	-----
INCREASE (DECREASE) IN CASH	5,343	(1,395,

Edgar Filing: MEDCOM USA INC - Form 10QSB

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	-	2,043,
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 5,343	\$ 648,
SUPPLEMENTAL CASH FLOW INFORMATION		
Interest paid	\$ 7,876	\$ 18,
Income taxes paid	\$ -	\$ 12,

See the accompanying notes to these unaudited financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2001 AND 2000

1. Basis of Presentation

The accompanying unaudited financial statements represent the financial position of MedCom USA, Inc. ("Company") as of December 31, 2001 and includes results of operations of the Company for the three and six months ended December 31, 2001 and cash flows for the six months ended December 31, 2001. These statements have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions for Form 10-QSB. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles ("GAAP") for complete financial statements. In the opinion of management, all adjustments to these unaudited financial statements necessary for a fair presentation of the results for the interim period presented have been made. The results for the three months ended December 31, 2001 may not necessarily be indicative of the results for the entire fiscal year. These financial statements should be read in conjunction with the Company's Form 10-KSB for the year ended June 30, 2001, including specifically the financial statements and notes to such financial statements contained therein.

2. Summary of Significant Accounting Policies

The accounting policies followed by the Company, and the methods of applying those policies, which affect the determination of its financial position, results of operations or cash flows are summarized below:

Cash and Cash Equivalents

Cash and cash equivalents include all short-term liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less. At times cash deposits may exceed government insured limits.

Concentration of Credit Risk

The Company maintains its cash balances in two banks in Islandia, New York, and one bank in Scottsdale, Arizona. The Federal Depository Insurance Corporation (FDIC) insures accounts at each institution up to \$100,000.

Inventories

Edgar Filing: MEDCOM USA INC - Form 10QSB

Inventories consist primarily of movie videocassettes that remain from a discontinued segment that was divested, and Point-of-Sale terminals and spare parts that are held for sale. Inventories are recorded at the lower of cost or market on a first-in, first-out basis.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets ranging from 3 to 5 years.

6

Revenue Recognition

Sales Revenue: The Company's revenues are derived from the sale of MedCard terminals, computer equipment and other items and are recognized upon shipment. Revenue from the licensing of software is recognized upon acceptance by the customer, if the license agreement includes such an acceptance provision, otherwise it is recognized upon shipment.

Service Fee Revenue: Revenue related to the processing of insurance eligibility verification and medical claim processing is recorded at the time the transaction is completed. Financial transactions involve approvals of credit card and debit card payments from the use of the terminals or personal computer and are recorded at the time the transaction is completed.

Income Taxes

The Company provides for income taxes based on the provisions of Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes, which, among other things, requires that recognition of deferred income taxes be measured by the provisions of enacted tax laws in effect at the date of financial statements.

Fair Value of Financial Instruments

Financial instruments consist primarily of accounts receivable, and obligations under accounts payable, accrued expenses, capital lease obligations and notes payable. The carrying amounts of accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value because of the short maturity of those instruments. The carrying value of the Company's capital lease arrangements approximates fair value because the instruments were valued at the retail cost of the equipment at the time the Company entered into the arrangements. The Company has applied certain assumptions in estimating these fair values. The use of different assumptions or methodologies may have a material effect on the estimates of fair values.

Net Loss Per Share

Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the year. The Company has adopted the provisions of Statement of Financial Accounting Standards No. 128, Earnings Per Share.

Edgar Filing: MEDCOM USA INC - Form 10QSB

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. This may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Stock-Based Compensation

Statements of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation, ("SFAS 123") established accounting and disclosure requirements using a fair-value based method of accounting for stock-based employee compensation. In accordance with SFAS 123, the Company has elected to continue accounting for stock based compensation using the intrinsic value method prescribed by Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees."

7

Intangible Assets

Intangible assets at December 31, 2001 consist of goodwill associated with the Company's acquisition of MedCard for the difference between the purchase price of the acquired business and the fair value of the identifiable net assets. Goodwill is amortized on a straight-line basis over 5 years.

Research and Development Expenditures

Research and development costs are expensed as incurred.

Impairment of Assets

The Company performs an assessment of impairment of long-lived assets periodically whenever there is an indication that the carrying amount of the asset may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted cash flows generated by those assets to the assets' net carrying value. The amount of impairment loss, if any, is measured as the difference between the net book value of the assets and the estimated fair value of the related assets.

Reclassifications

Certain reclassifications have been made to the financial statements for the three months and six months ended December 31, 2001, to conform with the presentation for accounts in the December 31, 2000 financial statements.

8

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained herein, the following

Edgar Filing: MEDCOM USA INC - Form 10QSB

discussion contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, but are not limited to, statements regarding future events and plans and expectations. Actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed elsewhere in this Form 10-QSB (incorporated herein Forward-Looking Statements).

OVERVIEW

MedCom USA, Inc. (the "Company") a Delaware corporation was formed in August 1991 under the name Sims Communications, Inc. The Company's primary business was providing telecommunications services. In 1996 the Company introduced four programs to broaden the Company's product and service mix: (a) cellular telephone activation, (b) sale of prepaid calling cards, (c) sale of long distance telephone service and (d) rental of cellular telephones using an overnight courier service. With the exception of the sale of prepaid calling cards, these four programs were discontinued in December 1997. During the fiscal year of 1998, the Company diversified its operations and moved into the area of medical information processing.

The Company changed its name to MedCom USA, Inc. in October 1999. During the fiscal years of 1999 and continuing through 2000, the Company directed its efforts in medical information processing. As of December 31, 2001, the Company currently operates the MedCard System (MedCard) that is deployed through a point-of-sale terminal or personal computer offering electronic transaction processing, as well as insurance eligibility verification. The Company has aggressively focused on its primary operations and core business in electronic Medical Transaction Processing.

MEDICAL TRANSACTION PROCESSING

MEDCARD SYSTEM

The Company provides innovative technology-based solutions for the healthcare industry that enable users to efficiently collect, utilize, analyze and disseminate data from payers, health care providers and patients. The MedCard System currently operates through a point-of-sale terminal or a personal computer. The point-of-sale terminals are purchased from Hypercom Corporation (Hypercom). The MedCard System also operates in a PC version and an on-line version is under development. The Company is in the process of assessing the feasibility of offering a service bundled package that would include an on-line enabled computer that has the capability of processing unlimited claims and eligibility verification for monthly fees. This application will be made available after the on-line version is available.

FINANCIAL SERVICES

The Company's credit card center and check services, provides the healthcare industry an unprecedented combination of services designed to improve collection and approvals of credit/debit card payments along with the added benefit and convenience of personal check guarantee from financial institutions.

Flex-pay is an accounts receivable management program that allows a provider to swipe a patient's credit card and store the patient's signature in the terminals, and bill the patient's card at a later date when it is determined what services rendered were not covered by the patient's insurance. Also, an easy-pay option is offered which allows patient's the added benefit and convenience of a one-time payment option or a recurring installment payments

Edgar Filing: MEDCOM USA INC - Form 10QSB

that will be processed on a specified date determined by the provider and patient. These options insure providers that payments are timely processed with the features of electronic accounts receivable management. These services are all deployed thorough point-of-sale terminals or a personal computer. Using the MedCard system, medical providers are relieved of the problems associated with billings and account management and lowers administrative documentation and costs.

PATIENT ELIGIBILITY

The MedCard System is also an electronic processing system that consolidates insurance eligibility verification, processes medical claims, and monitors referrals. The MedCard System allows a patient's primary care physician to request approval from the patient's insurance carrier or managed care plan for a referral to a secondary physician or specialist. The secondary physician or specialist can use the MedCard system to verify that referrals are approved by the patient's insurance carrier. The MedCard system's referral capabilities reduce documentation and administrative costs which results in increased productivity and greater patient information for the specialist, as well as a written record of the referral authorization.

The MedCard System can record and track encounters between patients and health care providers for performance evaluation and maintenance of records. After examining a patient a physician enters the patient's name, procedure code and diagnostic code at a nearby terminal. This information is then uploaded to MedCom's computer network, processed and transmitted back to the provider formatted in both summary and/or detailed reports, and as a result healthcare providers' reimbursements are accelerated and account receivables are reduced. The average time it takes the healthcare providers to collect payments from insurance carriers and plans decreases from an average of 89 days to 7 to 21 days. Health care providers will benefit from a 100% paperless claim processing system.

CUSTOMER SERVICE

The Company offers multiple training options for its products and services. Onsite training and teleconferencing, and a 24-hour technical support assistance are also features offered to Health care providers. Also, a 24-hour terminal replacement program and system upgrades are offered.

MARKETING STRATEGY

The MedCard System is marketed through the Company's sales personnel, and independent sales representatives and institutions such as EFS National Bank, Physicians Management Group, and Healthtech Systems. Company sales personnel generally receive a commission for the initial sale of the terminals, and collect a portion of residual income for the processing of insurance claims and verifying insurance eligibility. Independent sales representatives purchase the terminals directly from the Company and receive residual income.

10

REVENUES

Revenues from the MedCard system are generated through the sale of terminals, and processing insurance eligibility/verification, insurance claims, and financial transaction processing. The Company receives a fixed amount per terminal if the Company's sales personnel do not make sales. The Company also receives fees for each transaction processed through the MedCard System. Revenue sources include fees for financial transactions processed through the terminal, fees for collection of receivables if the Company provides billing services,

Edgar Filing: MEDCOM USA INC - Form 10QSB

fees associated with reimbursements made by insurance carriers for submitting claims that are processed electronically, fees for using the system's referral program and, fees for processing uploaded data. The Company also markets a complete billing service using the MedCard System for hospitals and large practice groups. The Company receives a percentage of the billing amount collected under these arrangements.

ADDITIONAL INFORMATION

Medcom files reports and other materials with the Securities and Exchange Commission. These documents may be inspected and copied at the Commission's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C., 20549. You can obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. You can also get copies of documents that the Company files with the Commission through the Commission's Internet site at www.sec.gov.

RESULTS OF OPERATIONS

Revenues for the quarter ended December 31, 2001 were \$135,891 as compared to during the quarter ended December 31, 2000 of \$252,541. The Company divested all of its business segments other than the MedCard business. The Company did not experience any significant changes in the volume in this segment as it concentrated on divesting of the other segments.

Cost of sales for the quarter ended December 31, 2001 was \$-0- as compared to quarter ended December 31, 2000 of \$150,291. The Company's cost of sales has decreased significantly and is attributed to the Company's ability to lease and finance equipment whereas in the past the Company was dependent on direct inventory equipment sales.

Selling expenses for the quarter ended December 31, 2000 experienced no expenditures in this area as compared quarter ended December 31, 2000 of \$435,689. This decrease was primarily the result of cost curtailment efforts and discontinued marketing expenditures for unprofitable business segments.

General and administrative expenses for quarter ended December 31, 2001 was \$511,357 as compared to quarter ended December 31, 2000 of \$1,449,195. These expenditures have been reduced due to reductions in personnel and consultant fees. Also, streamlining operations and divesting of unprofitable business segments has greatly contributed to this reduction.

Interest expense for the quarter ended December 31, 2001 was \$500 as compared to December 31, 2000 of \$13,980. Interest expense decreased as a result of decreases in outstanding debt by the company.

11

No tax benefit was recorded on the expected operating loss for the quarter ended December 31, 2001 as required by Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes. For the year ended we do not expect to realize the deferred tax asset and it is uncertain therefore we have provided a 100% valuation of the tax benefit and assets until we are certain to experience net profits in the future to fully realize the tax benefit and tax assets.

Net loss for the quarter ended December 31, 2001 was (\$450,129) or (\$0.02) per diluted share compared net loss for quarter ended December 31, 2000 of (\$2,643,571) or (\$0.39) per diluted share.

Edgar Filing: MEDCOM USA INC - Form 10QSB

LIQUIDITY AND CAPITAL RESOURCES

Cash used in operating activities for the six months ended December 31, 2001, was (\$468,834) as compared to cash used in operating activities for the six months ended December 31, 2000 of (\$2,752,339). The Company has significantly reduced its operating cash requirements as staffing was cut and other cost cutting measures were implemented. The Company increased its obligations under trade accounts payable and accrued expenses.

Cash used in investing activities for the six months ended December 31, 2001, was (\$160,034) as compared to cash used in investing activities for the six months ended December 31, 2000 of (\$1,176,112). This reduction is primarily the result of purchases of equipment for unprofitable business segments. As the Company has divested these unprofitable segments, the Company has succeeded in cost cutting measures.

Cash provided in financing activities was \$634,211 for the six months ended December 31, 2001 compared to cash provided from financing activities for the six months ended December 31, 2000 of \$2,533,352. This reduction in cash provided by financing activities is the direct result of proceeds received from the exercise of options and warrants.

The Company has arranged a credit facility with an equipment lessor whereby the Company sells terminals to the lessor when it has obtained a service contract with a customer. The Company in turn leases-back the terminals, generally under a 48-month repayment term. The amount of cash advanced is determined by the contract terms.

SOURCES OF CAPITAL

The Company has relied upon a shareholder to fund its operating cash flow deficiencies since June 30, 2001. This funding is accomplished in the form of common stock purchased at the closing price as of the date the funds are transferred to the Company. Management believes that current trends in its electronic transaction processing to the health care industries will provide positive cash flow to be self-sustaining from operations sometime in the near fiscal period. The amount of such will be dependent upon the rate of growth experienced and demand for the Company's product and services.

OTHER CONSIDERATIONS

There are numerous factors that affect our business and the results of its operations. Sources of these factors include general economic and business conditions, federal and state regulation of business activities, the level of demand for the Company's product or services, the level and intensity of

12

competition in the medical transaction processing industry and the pricing pressures that may result, the Company's ability to develop new services based on new or evolving technology and the market's acceptance of those new services, the Company's ability to timely and effectively manage periodic product transitions, the services, customer and geographic sales mix of any particular period, and the ability to continue to improve the infrastructure (including personnel and systems) to keep pace with the growth in its overall business activities.

FORWARD-LOOKING STATEMENTS

Except for historical information contained herein, this Form 10-QSB contains express or implied forward-looking statements within the meaning of

Edgar Filing: MEDCOM USA INC - Form 10QSB

Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company may make written or oral forward-looking statements from time to time in filings with the SEC, in press releases, or otherwise. The words "believes," "expects," "anticipates," "intends," "forecasts," "project," "plans," "estimates" and similar expressions identify forward-looking statements. Such statements reflect the current views with respect to future events and financial performance or operations and speak only as of the date the statements are made.

Forward-looking statements involve risks and uncertainties and readers are cautioned not to place undue reliance on forward-looking statements. The Company's actual results may differ materially from such statements. Factors that cause or contribute to such differences include, but are not limited to, those discussed elsewhere in this Form 10-QSB, as well as those discussed in Form 10-KSB which is incorporated by reference in this Form 10-QSB.

Management believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in such forward-looking statements will be realized. The inclusion of such forward-looking information should not be regarded, as a representation that the future events, plans, or expectations contemplated will be achieved. The Company undertakes no obligation to publicly update, review, or revise any forward-looking statements to reflect any change in expectations or any change in events, conditions, or circumstances on which any such statements based. Our filings with the SEC, including the Form 10-KSB, may be accessed at the SEC's web site, www.sec.gov.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

MedCom is involved in various legal proceedings and claims as described in our Form 10-KSB for the year ended June 30, 2001. No material developments occurred in any of these proceedings during the quarter ended December 3, 2001. The costs and results associated with these legal proceedings could be significant and could affect the results of future operations.

13

ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K

EXHIBITS

NO REPORTS ON FORM 8-K

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CERTIFICATION

Edgar Filing: MEDCOM USA INC - Form 10QSB

I, Bill Williams, President and Chief Executive Officer of MedCom USA, certify that:

1. I have reviewed this annual report on Form 10-QSB of MedCom USA;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; and
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report.

MEDCOM USA, INC.

By /s/ W.P. Williams

Chairman, President, CEO

September 18, 2002